Suppr超能文献

用于同步筛选激动剂和反向激动剂的构象型组胺H受体生物传感器的研发

Development of a Conformational Histamine H Receptor Biosensor for the Synchronous Screening of Agonists and Inverse Agonists.

作者信息

Schihada Hannes, Ma Xiaoyuan, Zabel Ulrike, Vischer Henry F, Schulte Gunnar, Leurs Rob, Pockes Steffen, Lohse Martin J

机构信息

Section of Receptor Biology & Signaling, Dept. Physiology & Pharmacology, Karolinska Institutet, Stockholm 171 77, Sweden.

Institute of Pharmacology and Toxicology and Rudolf Virchow Center, University of Würzburg, Würzburg 97070, Germany.

出版信息

ACS Sens. 2020 Jun 26;5(6):1734-1742. doi: 10.1021/acssensors.0c00397. Epub 2020 May 28.

Abstract

The histamine H receptor (HR) represents a highly attractive drug target for the treatment of various central nervous system disorders, but the discovery of novel HR targeting compounds relies on the assessment of highly amplified intracellular signaling events that do not only reflect HR modulation and carry the risk of high false-positive and -negative screening rates. To address these limitations, we designed an intramolecular HR biosensor based on the principle of bioluminescence resonance energy transfer (BRET) that reports the receptor's real-time conformational dynamics and provides an advanced tool to screen for both HR agonists and inverse agonists in a live cell screening-compatible assay format. This conformational G-protein-coupled receptor (GPCR) sensor allowed us to characterize the pharmacological properties of known and new H receptor ligands with unprecedented accuracy. Interestingly, we found that one newly developed H receptor ligand possesses even stronger inverse agonistic activity than reference HR inverse agonists including the current gold standard pitolisant. Taken together, we describe here the design and validation of the first screening-compatible HR conformational biosensor that will aid in the discovery of novel HR ligands and can be employed to gain deeper insights into the (in-)activation mechanism of this highly attractive drug target.

摘要

组胺H受体(HR)是治疗各种中枢神经系统疾病极具吸引力的药物靶点,但新型HR靶向化合物的发现依赖于对高度放大的细胞内信号事件的评估,这些事件不仅反映HR调节,还存在高假阳性和假阴性筛选率的风险。为了解决这些局限性,我们基于生物发光共振能量转移(BRET)原理设计了一种分子内HR生物传感器,该传感器可报告受体的实时构象动态,并提供一种先进工具,以活细胞筛选兼容的检测形式筛选HR激动剂和反向激动剂。这种构象G蛋白偶联受体(GPCR)传感器使我们能够以前所未有的准确性表征已知和新型H受体配体的药理学特性。有趣的是,我们发现一种新开发的H受体配体具有比包括当前金标准匹莫林在内的参考HR反向激动剂更强的反向激动活性。综上所述,我们在此描述了首个筛选兼容的HR构象生物传感器的设计和验证,该传感器将有助于发现新型HR配体,并可用于更深入了解这个极具吸引力的药物靶点的(失)活机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af8c/7325232/dfb094e555d3/se0c00397_0006.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验